Moderna (MRNA) announces U.S. expansion and 2023
By Michael Elkins
Moderna, Inc., (NASDAQ:MRNA) announced Friday that the biotechnology company is expanding its U.S. presence. The company plans to establish a corporate presence on the West Coast with new offices in South San Francisco, California and Seattle, Washington. Moderna also plans to hire approximately 2,000 new employees globally by the end of 2023.
Moderna’s West Coast presence joins additional U.S. locations in Cambridge, Massachusetts; Norwood, Massachusetts; Atlanta, Georgia; Bethesda, Maryland; and Princeton, New Jersey.
“Our team has continued to push beyond what we ever imagined possible to completely reimagine how medicines are created and delivered. We are making significant investments in both people and infrastructure to build the most impactful version of Moderna,” said Tracey Franklin, Chief Human Resources Officer of Moderna. “At Moderna, we give our people a platform to change medicine and an opportunity to change the world.”
Moderna’s new office in Seattle will provide technology solutions and further scale the implementation of artificial intelligence (AI) and cloud-based tools across the platform.
“Moderna is investing to fully realize our ambition of embedding technology into everything we do. By building technology solutions that enable business, scientific and people-led breakthroughs, we will continue to make a positive impact on the people we serve,” said Brad Miller, Chief Information Officer of Moderna. “We are hiring rapidly in-market across key tech capabilities and are excited to grow our presence in Seattle, an area rich in highly skilled talent.”
This U.S. expansion comes as Moderna is rapidly advancing its pipeline of mRNA medicines, including mRNA-4157, the company’s personalized cancer vaccine candidate.
Shares of MRNA are up 2.27% in mid-day trading on Friday.